What Does Retatrutide Do? How the Triple-Agonist Weight-Loss Drug Works

Retatrutide is an investigational once-weekly injection being studied for obesity, type 2 diabetes, and related metabolic conditions. It activates three hormone receptors—GLP-1, GIP, and glucagon—to reduce appetite, improve blood sugar regulation, slow stomach emptying, and possibly increase energy use. It is not FDA-approved yet and cannot be routinely prescribed 1.

What does retatrutide do in the body?

Retatrutide is designed to imitate and amplify signals from gut and pancreatic hormones that help control hunger, fullness, insulin secretion, and liver metabolism. In early studies, it was given as a once-weekly injection and studied in people with obesity, overweight, or type 2 diabetes 1, 2.

Researchers call retatrutide a triple hormone receptor agonist, or triple incretin agonist, because it activates three receptor systems: the GLP-1 receptor, the GIP receptor, and the glucagon receptor 1. Each receptor has a different role, so the drug is being studied for broader metabolic effects than single-target GLP-1 receptor agonists.

The honest answer is that we know more than we used to, but not enough for routine clinical use. Phase 2 trials give early signals on weight, HbA1c, lipids, blood pressure, and liver fat, while Phase 3 trials are designed to confirm whether benefits outweigh risks in larger and longer studies 1, 3.

How does retatrutide work for weight loss?

Retatrutide works by acting on appetite, satiety, blood sugar, and energy balance at the same time. Its three receptor targets are the main reason researchers think it may produce larger average weight changes than older incretin drugs, though direct head-to-head trial data are limited 1.

GLP-1: appetite, fullness, and slower stomach emptying

GLP-1 stands for glucagon-like peptide-1. GLP-1 receptor activation helps increase fullness, reduce appetite, slow gastric emptying, and support glucose-dependent insulin secretion, which is why GLP-1 medicines are used in obesity and type 2 diabetes care 4, 5.

GIP: insulin signaling and metabolic effects

GIP stands for glucose-dependent insulinotropic polypeptide. GIP receptor activity is involved in insulin secretion after meals and may affect fat tissue signaling; tirzepatide, a dual GIP/GLP-1 receptor agonist, supports the idea that GIP plus GLP-1 activity can be clinically useful in obesity and diabetes care 6, 7.

Glucagon receptor activity: energy use and liver metabolism

Glucagon is often known as a blood-sugar-raising hormone, but glucagon receptor activity also affects liver metabolism and energy expenditure. Retatrutide’s glucagon receptor activity is one reason it is being studied for metabolic dysfunction-associated steatotic liver disease, also called fatty liver disease 8.

This same mechanism could also create trade-offs. Any drug that changes appetite, gut movement, insulin signaling, and liver metabolism can cause side effects, and retatrutide trials have reported gastrointestinal adverse events such as nausea, vomiting, diarrhea, and constipation 1, 2.

How much weight loss has retatrutide shown in studies?

Retatrutide has shown large average weight changes in Phase 2 obesity research, but trial results do not predict what will happen for one person. In the Phase 2 obesity trial, participants received once-weekly retatrutide at study-assigned doses up to 12 mg for 48 weeks 1.

In that trial, adults with obesity or overweight and weight-related conditions were randomly assigned to retatrutide or placebo. The study reported dose-related weight reduction over 48 weeks, along with gastrointestinal side effects that were usually more common during dose escalation 1.

Eli Lilly has also described Phase 3 programs for retatrutide, including TRIUMPH studies for obesity-related conditions and TRANSCEND-T2D studies for type 2 diabetes. These programs matter because larger Phase 3 trials are usually needed before regulators can decide whether a drug should be approved 3, 9.

Large weight loss can include both fat mass and lean mass. That is why obesity care often discusses protein intake, resistance training, side-effect management, and monitoring for gallbladder disease or dehydration during major weight change 10, 11.

Does retatrutide burn belly fat?

Retatrutide is not a spot-fat-loss drug. No medication can choose only belly fat, but overall weight loss can reduce abdominal and visceral fat over time; retatrutide has also been studied for liver fat, a related marker of metabolic fat 8.

In a Phase 2 trial in people with metabolic dysfunction-associated steatotic liver disease, retatrutide was studied for liver-fat reduction and broader cardiometabolic changes. The study reported changes in liver fat and body weight, but also reported gastrointestinal side effects, so benefits and tolerability have to be weighed together 8.

Belly size can change for several reasons: fat loss, less bloating, fluid shifts, or changes in digestion. Retatrutide’s effect on gastric emptying and appetite could change how a person feels after meals, but it should not be understood as targeted abdominal fat burning 1.

Can you gain muscle on retatrutide?

Retatrutide is being studied as a weight-loss and metabolic drug, not as a muscle-gain medication. During major weight loss, some lean mass loss can happen, so muscle-preserving habits are often part of safe obesity care 10.

Lean mass includes muscle, water, organs, and connective tissue. A person may improve strength while losing weight if they do resistance training and eat enough protein, but that is not the same as the drug directly building muscle 10, 11.

Before changing diet, exercise, supplements, or medication, it is best to talk with a clinician. This is especially important for people with diabetes, kidney disease, eating-disorder history, gallbladder disease, or medicines that can cause low blood sugar 4, 6.

What are the possible benefits of retatrutide?

Retatrutide is being investigated for weight reduction, blood sugar improvement, fatty liver disease, obstructive sleep apnea, and knee osteoarthritis. The key word is “investigated”: these possible benefits need full regulatory review before retatrutide can be used as a routine prescription drug 3, 9.

• Weight reduction: Phase 2 obesity data showed dose-related weight change over 48 weeks, with gastrointestinal adverse events also reported 1.
• Blood sugar: a Phase 2 trial in type 2 diabetes studied changes in HbA1c and body weight, while also tracking adverse events 2.
• Blood pressure and cholesterol: obesity and diabetes studies reported cardiometabolic signals such as lipid and blood-pressure changes, but these need confirmation in larger trials 1, 2.
• Fatty liver disease: retatrutide has been studied in metabolic dysfunction-associated steatotic liver disease, including liver fat outcomes 8.
• Sleep apnea and knee osteoarthritis: Phase 3 TRIUMPH studies include obesity-related conditions such as obstructive sleep apnea and knee osteoarthritis, including outcomes like apnea severity and WOMAC pain score 3, 9.

Possible benefits should never be separated from risks. Retatrutide trials have reported nausea, diarrhea, vomiting, constipation, and other adverse events, and related incretin medicines carry warnings or precautions for pancreatitis, gallbladder disease, kidney injury from dehydration, and certain contraindications 1, 4, 6.

What are the cons and risks of retatrutide?

Retatrutide has not completed the full FDA review process, so the biggest risk is uncertainty. Phase 2 studies are useful, but they cannot answer every long-term safety question, especially over years of use 1, 2.

• Common trial side effects: nausea, vomiting, diarrhea, constipation, and other gastrointestinal adverse events were reported in retatrutide studies 1, 2.
• Related incretin risks: semaglutide and tirzepatide labels include warnings or precautions for pancreatitis, gallbladder disease, acute kidney injury, severe gastrointestinal reactions, and hypoglycemia when used with insulin or insulin secretagogues 4, 6.
• Contraindications may matter: FDA-approved semaglutide and tirzepatide products carry boxed warnings about thyroid C-cell tumors and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 4, 6.
• Unknowns remain: long-term cardiovascular, gallbladder, pancreatic, liver, and tolerability outcomes need larger studies and regulatory review 3, 9.

Is retatrutide FDA-approved or available by prescription?

Retatrutide is not FDA-approved and is not available for routine prescribing. As of July 2026, it remains an investigational drug being studied in clinical trials 3, 9.

For a new drug to become available through standard prescribing, the manufacturer generally must complete adequate clinical trials, submit data to the FDA, and receive FDA approval for a specific indication. Until that happens, retatrutide should not be described as an available prescription weight-loss medication 12.

Chia does not offer retatrutide. We also do not describe retatrutide as something that can be compounded or shipped through our pharmacy partners, because it is not in our live catalog and remains investigational.

How does retatrutide compare with semaglutide and tirzepatide?

Retatrutide, semaglutide, and tirzepatide all act on incretin-related pathways, but they are not the same drug. The key difference is receptor targeting: semaglutide targets 1 receptor family, tirzepatide targets 2, and retatrutide targets 3 1, 4, 6.

Head-to-head comparisons are limited. It is not accurate to say retatrutide is “better” than semaglutide or tirzepatide until larger studies and direct comparisons clarify benefits, side effects, durability, and who is most likely to respond 1, 6, 7.

What weight-loss medication options are available at Chia while retatrutide is still investigational?

Chia does not offer retatrutide. While retatrutide remains investigational, our current medical weight-loss options include compounded semaglutide injection and compounded tirzepatide tablets or injection, prescribed only after a licensed-provider review when clinically appropriate.

At Chia, treatment starts online with a short health questionnaire. A licensed US provider reviews health history, current medications, contraindications, and goals before deciding whether prescription treatment is appropriate; a prescription is never guaranteed.

If prescribed, medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. Patients can message their care team through the portal, and dosing is provider-guided and adjusted over time, including microdosing plans for semaglutide and tirzepatide when clinically appropriate.

You can learn more about compounded semaglutide injection, compounded tirzepatide tablets or injection, the Weight + Energy protocol, or the Weight + Muscle protocol. If you want to know whether current options may fit your situation, you can start with Chia’s online eligibility quiz.

Who should talk with a clinician about medical weight-loss treatment?

Medical weight-loss treatment may be worth discussing if weight is affecting health, mobility, blood sugar, blood pressure, sleep, or daily life. Eligibility depends on the full clinical picture, not just a scale number or BMI 11.

• Ask what benefits are realistic for your health history and goals.
• Ask which side effects need urgent attention, such as severe belly pain, ongoing vomiting, dehydration, or signs of gallbladder disease 4, 6.
• Ask how your clinician will monitor blood sugar, blood pressure, kidney function, nutrition, and medication interactions when needed 11.
• Ask how to protect lean mass during weight loss, including protein, resistance training, and follow-up support 10.
• Ask whether any use would be on-label or off-label; some medications may be prescribed in ways that differ from FDA-approved labeling when a clinician determines it is appropriate.

FAQ

Keep reading

Weight Loss

GLP-1 Peptides Explained: How They Work, Who They Help, and How to Get One

Weight Loss

How to Get Weight Loss Medication: Eligibility, Options, and Costs

GLP-1 & Weight Loss

Reta Peptide (Retatrutide): How the Triple-Receptor GLP-1/GIP/Glucagon Agonist Works